

- B3
15. A vaccine for protecting chickens from exposure to virulent infectious bronchitis virus, wherein said vaccine is not serially passaged through tissue culture, comprising: a solution containing, on a chicken egg basis, a live avirulent strain of infectious bronchitis virus in an immunogenically-effective amount.

Please add the following new claims:

- Sub. E2
- B4
19. A non-serially passaged poultry vaccine against infectious bronchitis virus (IBV) comprising a live avirulent strain of infectious bronchitis virus in an immunogenically effective amount for in ovo administration.
20. The vaccine of claim 19, wherein said vaccine comprises about  $10^{-1.0}$  EID<sub>50</sub> per dose to about  $10^{2.0}$  EID<sub>50</sub> per dose.
21. The vaccine of claim 20, wherein said vaccine comprises about  $10^{0.0}$  EID<sub>50</sub> per dose to about  $10^{2.0}$  EID<sub>50</sub> per dose.
- Sub. C5
22. The vaccine of claim 20, wherein said vaccine comprises about  $10^{0.0}$  EID<sub>50</sub> per dose to about  $10^{1.0}$  EID<sub>50</sub> per dose.

### REMARKS

Reconsideration and allowance of the application are respectfully requested in light of the foregoing amendments and the following remarks.

Claims 1 – 16 are pending in the application. Claim 1 has been amended to more succinctly specify that the host animal is "poultry". Claims 1, 13 and 15 have also been amended to recite that the subject vaccine is "not serially passaged". As that term is used herein, "not serially passaged" means that the vaccine, once prepared, is not then serially administered and passaged through tissue culture to reduce its pathogenicity prior to its ultimate administration to individual poultry members. Support for this amendment may be found in the specification with reference to Example 1 bridging pages 5 and 6. It is here that this feature of the invention is implicitly set forth.

New claims 19 – 22 are each directed to additional and somewhat more preferred embodiments of the invention. Their inclusion should not be construed as diminishing the patentability of the originally filed claims.

Entry of the foregoing amendments and new claims is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the amendments set forth above. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."